Letter to the Editor: From association to mechanism - advancing the understanding of small intestinal bacterial overgrowth in acute pancreatitis.

Small intestinal bacterial overgrowth (SIBO) has emerged as a potential contributor to gastrointestinal dysfunction and systemic inflammation in acute pancreatitis (AP). The recent study by Kumbar et al provides important prospective evidence demonstrating a substantially higher prevalence of SIBO among patients with AP than healthy controls and identifies several clinical variables associated with bacterial overgrowth. Rather than reiterating the methodological limitations acknowledged by the authors, we discuss how these findings fit within the evolving understanding of the gut-pancreas axis and highlight emerging opportunities for precision microbiome research in AP. Particular attention is given to intestinal methanogen overgrowth, a biologically distinct entity that may influence intestinal motility, disease phenotype, and therapeutic response. We further outline future research priorities, including longitudinal microbiome profiling, integration of microbial biomarkers with clinical severity indices, and phenotype-directed therapeutic strategies. These perspectives extend the clinical implications of the index study and underscore the need to move beyond prevalence estimates toward mechanistic and translational investigations that clarify the causal role of microbial dysbiosis in AP.